

Multiple Myeloma Treatments

Reference Number: RDF1658-23

Date of Response: 20/07/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Dear Royal Devon University Healthcare NHS Foundation Trust,

1. *Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.*

Answer: 201 patients.

2. *Of the multiple myeloma patients over the past 6 month, how many were treated with the following:*

Answer: Please see below representing the latest 6 months available – October 2022 to April 2023.

	Total
<i>Belantamab Mafodotin [Blenrep]</i>	Nil
<i>Bortezomib [Velcade] monotherapy or with dexamethasone</i>	Nil
<i>Bortezomib, thalidomide and dexamethasone [VTD]</i>	≤5
<i>Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)</i>	19
<i>Carfilzomib [Kyprolis] and dexamethasone</i>	Nil
<i>Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone</i>	≤5
<i>Daratumumab [Darzalex] monotherapy</i>	28
<i>Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)</i>	15
<i>Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)</i>	13
<i>Elranatamab</i>	Nil
<i>Idecabtagene vicleucel [Abecma]</i>	Nil
<i>Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)</i>	9
<i>Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd)</i>	24

<i>Lenalidomide [Revlimid] monotherapy</i>	67
<i>Lenalidomide [Revlimid] and dexamethasone</i>	Nil
<i>Pomalidomide [Imnovid] and dexamethasone</i>	6
<i>Selinexor and dexamethasone</i>	Nil
<i>Talquetamab</i>	Nil
<i>Teclistamab [Tecvayli]</i>	Nil
<i>Any other systemic anti-cancer therapy</i>	35

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤ 5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.